AstraZeneca: bronchodilator fails Phase III COPD trial
(CercleFinance.com) - In a late-stage trial, AstraZeneca failed to show that a new treatment for chronic obstructive pulmonary disease demonstrated superiority (COPD).
In the Phase IIIb trial, Bevespi Aerosphere demonstrated non-inferiority to umeclidinium/vilanterol on peak forced expiratory volume in one second (FEV1), but did not demonstrate superiority on peak FEV1, the drugmaker said.
Furthermore, the fixed-dose dual bronchodilator did not demonstrate non-inferiority on trough FEV1, the group said.
In the study, 1,119 patients were randomised to receive two inhalations twice a day.
AstraZeneca shares are currently down 0.1% in London after these results were announced.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In the Phase IIIb trial, Bevespi Aerosphere demonstrated non-inferiority to umeclidinium/vilanterol on peak forced expiratory volume in one second (FEV1), but did not demonstrate superiority on peak FEV1, the drugmaker said.
Furthermore, the fixed-dose dual bronchodilator did not demonstrate non-inferiority on trough FEV1, the group said.
In the study, 1,119 patients were randomised to receive two inhalations twice a day.
AstraZeneca shares are currently down 0.1% in London after these results were announced.
Copyright (c) 2018 CercleFinance.com. All rights reserved.